FDA appropriation stalls
This article was originally published in The Tan Sheet
Executive Summary
The House Appropriations Committee postpones a markup of fiscal 2011 agriculture funding legislation, leaving FDA funding in limbo. The House adjourned for August recess without taking action, leaving fiscal 2011 funding levels undetermined until Congress returns the week of Sept. 13. With all House members and some of the Senate soon to focus on elections, chances are growing for an omnibus bill or continuing resolution to fund federal agencies at the start of the next fiscal year (1"The Tan Sheet" July 26, 2010)
You may also be interested in...
FDA Funding Not Set As Chances Grow For Omnibus Or Continuing Resolution
FDA's fiscal 2011 funding is not the only decision Congress has yet to make - lawmakers likely will face passing either an omnibus spending bill or a continuing resolution to keep the federal government operating past the end of the current fiscal year
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.